KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Invested Capital: 2009-2025

Historic Invested Capital for Neogenomics (NEO) over the last 16 years, with Sep 2025 value amounting to $838.3 million.

  • Neogenomics' Invested Capital fell 7.70% to $838.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $838.3 million, marking a year-over-year decrease of 7.70%. This contributed to the annual value of $902.3 million for FY2024, which is 4.16% down from last year.
  • Per Neogenomics' latest filing, its Invested Capital stood at $838.3 million for Q3 2025, which was down 1.84% from $854.0 million recorded in Q2 2025.
  • Neogenomics' 5-year Invested Capital high stood at $1.1 billion for Q2 2021, and its period low was $838.3 million during Q3 2025.
  • In the last 3 years, Neogenomics' Invested Capital had a median value of $915.9 million in 2024 and averaged $913.6 million.
  • In the last 5 years, Neogenomics' Invested Capital surged by 40.32% in 2021 and then dropped by 10.93% in 2022.
  • Quarterly analysis of 5 years shows Neogenomics' Invested Capital stood at $1.1 billion in 2021, then declined by 9.95% to $998.0 million in 2022, then declined by 5.66% to $941.5 million in 2023, then declined by 4.16% to $902.3 million in 2024, then dropped by 7.70% to $838.3 million in 2025.
  • Its Invested Capital was $838.3 million in Q3 2025, compared to $854.0 million in Q2 2025 and $888.3 million in Q1 2025.